The graph presents the proportion of participants that were heterozygous for the p.Val50Met variants (labeled as 1) versus TTR+ participants without the p.Val50Met variant (labeled as 0), according to the main principal component of the study, namely, the polyneuropathy (PN), cardiomyopathy (CM), gastrointestinal (GI), and general symptoms (GS) components. This evidence concerns the gene TTR and cutaneous mastocytosis.